采用3D打印技术制作了一种具有超柔性支架结构和圆形横截面支架的新型紫杉醇洗脱生物可吸收血管支架。

IF 8.1 1区 医学 Q1 MATERIALS SCIENCE, BIOMATERIALS
Regenerative Biomaterials Pub Date : 2025-07-09 eCollection Date: 2025-01-01 DOI:10.1093/rb/rbaf073
Wei Liu, Qingqing Li, Ge Song, Zhiqi Lin, Xiaofei Gong, Hanqing Feng, Hugh Q Zhao, Yujie Zhou, Yunbing Wang, Zhongyong Fan, Qing Liu
{"title":"采用3D打印技术制作了一种具有超柔性支架结构和圆形横截面支架的新型紫杉醇洗脱生物可吸收血管支架。","authors":"Wei Liu, Qingqing Li, Ge Song, Zhiqi Lin, Xiaofei Gong, Hanqing Feng, Hugh Q Zhao, Yujie Zhou, Yunbing Wang, Zhongyong Fan, Qing Liu","doi":"10.1093/rb/rbaf073","DOIUrl":null,"url":null,"abstract":"<p><p>Bioresorbable stents (BRS) have emerged as a groundbreaking development in the field of percutaneous coronary intervention (PCI) as they address the long-standing concerns of metallic stents. Nevertheless, the observed higher thrombosis rates in the first generation BRS, i.e. ABSORB<sup>®</sup>, might be attributed to their thicker struts, slower degradation rate and structural dismantling of partially endothelialized stents. In this study, measures have been taken to overcome these limitations include reducing strut thickness, modifying the structural design to maintain radial strength with thinner round cross section struts and using a new material poly(L-lactide-co-ɛ-caprolactone) (PLCL 95/5) that is tougher and degrade faster than poly(L-lactic acid) (PLLA).Given the excellent biocompatibility of PLCL materials, the US FDA has approved their use in clinical applications. PLCL stents can be used to treat diseases such as tracheal stenosis and tracheoesophageal fistula, and can also be applied in the construction of other tissue engineering stents, such as nerve conduitsand fat filling stents. The newly designed coronary stents were fabricated using a 3D printing technology with a rotating platform, coated with a paclitaxel coating and comprehensive in vitro research was conducted. It was the first to undergo tests in animals. Results showed the novel paclitaxel eluting PLCL stents had super-flexible structure, thinner round cross-sectional struts, a faster degradation profile and satisfactory hemocompatibility. With a paclitaxel dose of 0.57 μg/mm<sup>2</sup>, the drug eluting stents showed very low degree of stenosis within 6 months of implantation in a porcine model. Overall, the results showed that the novel 3D printed PLCL drug eluting stent is a very promising candidate for next generation bioresorbable coronary stent.</p>","PeriodicalId":20929,"journal":{"name":"Regenerative Biomaterials","volume":"12 ","pages":"rbaf073"},"PeriodicalIF":8.1000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371334/pdf/","citationCount":"0","resultStr":"{\"title\":\"A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.\",\"authors\":\"Wei Liu, Qingqing Li, Ge Song, Zhiqi Lin, Xiaofei Gong, Hanqing Feng, Hugh Q Zhao, Yujie Zhou, Yunbing Wang, Zhongyong Fan, Qing Liu\",\"doi\":\"10.1093/rb/rbaf073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bioresorbable stents (BRS) have emerged as a groundbreaking development in the field of percutaneous coronary intervention (PCI) as they address the long-standing concerns of metallic stents. Nevertheless, the observed higher thrombosis rates in the first generation BRS, i.e. ABSORB<sup>®</sup>, might be attributed to their thicker struts, slower degradation rate and structural dismantling of partially endothelialized stents. In this study, measures have been taken to overcome these limitations include reducing strut thickness, modifying the structural design to maintain radial strength with thinner round cross section struts and using a new material poly(L-lactide-co-ɛ-caprolactone) (PLCL 95/5) that is tougher and degrade faster than poly(L-lactic acid) (PLLA).Given the excellent biocompatibility of PLCL materials, the US FDA has approved their use in clinical applications. PLCL stents can be used to treat diseases such as tracheal stenosis and tracheoesophageal fistula, and can also be applied in the construction of other tissue engineering stents, such as nerve conduitsand fat filling stents. The newly designed coronary stents were fabricated using a 3D printing technology with a rotating platform, coated with a paclitaxel coating and comprehensive in vitro research was conducted. It was the first to undergo tests in animals. Results showed the novel paclitaxel eluting PLCL stents had super-flexible structure, thinner round cross-sectional struts, a faster degradation profile and satisfactory hemocompatibility. With a paclitaxel dose of 0.57 μg/mm<sup>2</sup>, the drug eluting stents showed very low degree of stenosis within 6 months of implantation in a porcine model. Overall, the results showed that the novel 3D printed PLCL drug eluting stent is a very promising candidate for next generation bioresorbable coronary stent.</p>\",\"PeriodicalId\":20929,\"journal\":{\"name\":\"Regenerative Biomaterials\",\"volume\":\"12 \",\"pages\":\"rbaf073\"},\"PeriodicalIF\":8.1000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371334/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regenerative Biomaterials\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1093/rb/rbaf073\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative Biomaterials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1093/rb/rbaf073","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

摘要

生物可吸收支架(BRS)解决了金属支架长期存在的问题,是经皮冠状动脉介入治疗(PCI)领域的突破性发展。然而,第一代BRS(即吸收®)中观察到的较高血栓发生率可能归因于其更厚的支架,更慢的降解速度和部分内皮支架的结构拆除。在这项研究中,为了克服这些限制,研究人员采取了一些措施,包括减少支撑厚度,修改结构设计以保持径向强度,使用更薄的圆截面支撑,以及使用一种比聚l -乳酸(PLLA)更坚韧、降解更快的新材料聚l -乳酸-co- α -己内酯(PLCL 95/5)。鉴于PLCL材料优异的生物相容性,美国FDA已批准其在临床应用中使用。PLCL支架可用于治疗气管狭窄、气管食管瘘等疾病,也可用于其他组织工程支架的构建,如神经导管、脂肪填充支架等。新设计的冠状动脉支架采用旋转平台3D打印技术制作,涂覆紫杉醇涂层,并进行全面的体外研究。这是第一次在动物身上进行试验。结果表明,新型紫杉醇洗脱PLCL支架具有超柔性结构、较薄的圆形横撑、较快的降解曲线和良好的血液相容性。紫杉醇剂量为0.57 μg/mm2时,药物洗脱支架在猪模型植入6个月内狭窄程度极低。综上所述,新型3D打印PLCL药物洗脱支架是下一代生物可吸收冠状动脉支架非常有前景的候选材料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.

A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.

A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.

A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.

Bioresorbable stents (BRS) have emerged as a groundbreaking development in the field of percutaneous coronary intervention (PCI) as they address the long-standing concerns of metallic stents. Nevertheless, the observed higher thrombosis rates in the first generation BRS, i.e. ABSORB®, might be attributed to their thicker struts, slower degradation rate and structural dismantling of partially endothelialized stents. In this study, measures have been taken to overcome these limitations include reducing strut thickness, modifying the structural design to maintain radial strength with thinner round cross section struts and using a new material poly(L-lactide-co-ɛ-caprolactone) (PLCL 95/5) that is tougher and degrade faster than poly(L-lactic acid) (PLLA).Given the excellent biocompatibility of PLCL materials, the US FDA has approved their use in clinical applications. PLCL stents can be used to treat diseases such as tracheal stenosis and tracheoesophageal fistula, and can also be applied in the construction of other tissue engineering stents, such as nerve conduitsand fat filling stents. The newly designed coronary stents were fabricated using a 3D printing technology with a rotating platform, coated with a paclitaxel coating and comprehensive in vitro research was conducted. It was the first to undergo tests in animals. Results showed the novel paclitaxel eluting PLCL stents had super-flexible structure, thinner round cross-sectional struts, a faster degradation profile and satisfactory hemocompatibility. With a paclitaxel dose of 0.57 μg/mm2, the drug eluting stents showed very low degree of stenosis within 6 months of implantation in a porcine model. Overall, the results showed that the novel 3D printed PLCL drug eluting stent is a very promising candidate for next generation bioresorbable coronary stent.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Regenerative Biomaterials
Regenerative Biomaterials Materials Science-Biomaterials
CiteScore
7.90
自引率
16.40%
发文量
92
审稿时长
10 weeks
期刊介绍: Regenerative Biomaterials is an international, interdisciplinary, peer-reviewed journal publishing the latest advances in biomaterials and regenerative medicine. The journal provides a forum for the publication of original research papers, reviews, clinical case reports, and commentaries on the topics relevant to the development of advanced regenerative biomaterials concerning novel regenerative technologies and therapeutic approaches for the regeneration and repair of damaged tissues and organs. The interactions of biomaterials with cells and tissue, especially with stem cells, will be of particular focus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信